Business Wire

STV to Deploy Post-Quantum’s Secure Communications Platform, Forms Strategic Cooperation to Deliver Next-Generation Security

4.11.2025 10:00:00 CET | Business Wire | Press Release

Share

STV Group a.s. (“STV”), one of the world’s fastest-growing defence innovators, has signed a multi-year licence agreement to use Post-Quantum’s groundbreaking quantum-safe communications platform and signed a Strategic Cooperation Agreement to accelerate deployment across Europe, NATO, and global defence markets. With quantum computing threatening to render traditional encryption obsolete, the move positions STV at the forefront of the cybersecurity revolution - arming governments, defence forces, and enterprises with next-generation resilience against “Harvest Now, Decrypt Later” attacks.

By fusing Post-Quantum’s NATO-tested modular platform with its own world-class defence solutions, STV is setting a new global benchmark for secure communications and digital trust. Together, the two companies are delivering the most advanced, future-proof systems to protect sensitive data and mission-critical operations - ensuring that even in the quantum era, allied communications remain impenetrable.

The partnership represents a decisive leap forward, combining STV’s defence innovation track record with Post-Quantum’s pioneering expertise to deliver communications and data protection systems that go beyond current industry standards.

JUDr. Pavel Kudrhalt, CEO of STV, said: “This isn’t just about acquiring technology - it’s about building an uncompromising, end-to-end secure ecosystem for the future. Our customers demand full supply chain assurance, from manufacturing and tamper-proof transport to deployment and monitoring. With the rising threat of ‘Harvest Now, Decrypt Later’ attacks, quantum-safe defences are no longer optional. Post-Quantum’s platform doesn’t just lead the field - it allows STV to be the first-mover to redefine the very standards of digital trust in defence solutions. By embedding their technology into our portfolio, we are giving NATO allies, EU partners, and national clients the strongest possible protection for the quantum era - whether that’s safeguarding command and control chains, operating mission-critical drones, or deploying munitions in battlefield communications.”

Rikky Hasan, CEO of Post-Quantum, added: “STV’s vision and leadership in defence innovation make them the ideal partner. Together we are unleashing a new wave of secure, quantum-safe solutions that protect the world’s most sensitive data against today’s adversaries and tomorrow’s quantum threats. Our modular approach to Identity, Transmission and Encryption - already proven in NATO environments - offers the fastest and most agile way to integrate into STV’s global portfolio. This is a proud moment for both companies, and a milestone for global cybersecurity.”

This acquisition and alliance signal the dawn of a new era: one where quantum-resilient platforms are no longer optional, but essential. United by a shared mission to safeguard the future, STV and Post-Quantum are leading the charge toward a world where critical communications remain impenetrable - even in the face of quantum computing’s disruptive power.

About STV

STV Group a.s. is one of Europe’s fastest-growing defence innovators, delivering advanced security and defence solutions to governments, NATO allies, and commercial partners worldwide. Headquartered in the Czech Republic, the company combines cutting-edge engineering with a bold vision for the future of security.

Building on a century of industrial tradition, STV Group has become the Czech Republic’s leading producer of munitions, loitering systems, armoured vehicle platforms and integrated lifecycle services. The group is also a European leader in ecological disposal and demilitarisation of surplus ammunition, underscoring its commitment to safety and sustainability. With NATO-tested technologies and global partnerships, STV Group is trusted to deliver the resilient, future-proof capabilities that keep nations secure in an era of emerging threats.

About Post-Quantum

Post-Quantum is leading the charge into the quantum era by upgrading the world’s encryption. Its quantum-safe platform protects organisations across their entire digital footprint with modular software for Identity, Transmission, and Encryption—designed to be interoperable, crypto-agile and seamlessly backward compatible.

Already trusted by NATO, critical national infrastructure providers, and major financial institutions, Post-Quantum has a proven track record in safeguarding mission-critical data. The company is the inventor of NTS-KEM (now known as Classic McEliece in the NIST competition) and the author of the IETF’s Hybrid Post-Quantum VPN standard, which is now the global benchmark for secure connectivity. With its pioneering technologies, Post-Quantum is ensuring the world stays one step ahead of the quantum threats.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104052022/en/

Contacts

For further information, please contact:
Fire on the Hill
Nick Ward. +44 (0)7821 474 272
nward@fireoth.com
postquantum@fireoth.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press Release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press Release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press Release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press Release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press Release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye